shortagewatch

Home / Sensory organs / Nepafenac

ATC S01BC10 · Antiinflammatory Agents, Non-Steroids · updated 2 Nov 2026

Nepafenac shortage

As of 2 Nov 2026, Nepafenac has a reported shortage in 1 of the 16 countries we track (Canada), covering 2 products from 1 company.

Is there a Nepafenac shortage?

Yes. As of 2 Nov 2026, Nepafenac is reported short in 1 of the 16 countries we track: Canada. The earliest expected return is 30 Jun 2027 (Canada). 1 of 2 affected products have no return date.

Countries1/16
Products2packs or presentations
Companies11 listed
Short since20 Jul 20263 months ago
Earliest return30 Jun 2027company estimate
Main reasonActive ingredient shortage

Timeline

Canada
ILEVRO (1 bottle of 3 mL)ILEVRO (1 bottle of 3 mL)today

Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.

Which companies are short

products short, all countries
Novartis2 NOVN

Listed: Novartis NOVN · SIX Swiss

Compared with similar medicines

ATC group S01BC · Antiinflammatory Agents, Non-Steroids
Diclofenac8/16Bromfenac3/16Indometacin1/16Ketorolac1/16Nepafenac1/16

Affected products

CountryProductCompanySinceExpected backReason
CAILEVRO (1 bottle of 3 mL)NOVARTIS PHARMACEUTICALS CANADA INC20 Jul 2026not givenActive ingredient shortage
Shortage of an active ingredient
CAILEVRO (1 bottle of 3 mL) discontinuationNOVARTIS PHARMACEUTICALS CANADA INCnot given30 Jun 2027Not stated

"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.

Questions

Is there a Nepafenac shortage?

Yes. As of 2 Nov 2026, Nepafenac is reported short in 1 of the 16 countries we track: Canada. The earliest expected return is 30 Jun 2027 (Canada). 1 of 2 affected products have no return date.

When will Nepafenac be back in stock?

Companies expect supply back from 30 Jun 2027 in Canada; Canada: 30 Jun 2027. These are company estimates reported to each authority.

Why is Nepafenac in short supply?

The most common reason reported is: active ingredient shortage. Reasons by product are listed in the table below.

Which companies have Nepafenac shortages?

Novartis.